Evidence map›Paper›PMID 41675564›Full record

ArticleJPRAS open2026

Impact of intravenous tranexamic acid administration on reduction mammoplasty outcomes.

Stephanie Francalancia, Mary Lou, Kathryn Leeke, Margaret Wang, Damon McIntire, Nikhil Sobti, Daniel Kwan, Lauren Roussel, Amy Maselli, Rachel Sullivan and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JPRAS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Stephanie FrancalanciaDivision of Plastic and Reconstructive Surgery, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
Mary LouDivision of Plastic and Reconstructive Surgery, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
Kathryn LeekeDivision of Plastic and Reconstructive Surgery, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
Margaret WangDivision of Plastic and Reconstructive Surgery, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
Damon McIntireDivision of Plastic and Reconstructive Surgery, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
Nikhil SobtiDivision of Plastic and Reconstructive Surgery, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
Daniel KwanDivision of Plastic and Reconstructive Surgery, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
Lauren RousselDivision of Plastic and Reconstructive Surgery, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
Amy MaselliDivision of Plastic and Reconstructive Surgery, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
Rachel SullivanDivision of Plastic and Reconstructive Surgery, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
Paul LiuDivision of Plastic and Reconstructive Surgery, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
Karl BreuingDivision of Plastic and Reconstructive Surgery, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The growing use of tranexamic acid (TXA) in plastic surgery warrants an accurate analysis of efficacy for body contouring indications. We offer the largest cohort evaluation of intravenous TXA use in minimizing postoperative complications following reduction mammoplasty. Methods: A single-institution retrospective analysis was conducted on consecutive reduction mammoplasty procedures performed between February 2023-August 2024. Patient demographics, intraoperative factors, and postoperative complications were collected and summarized using descriptive statistics. Groups were stratified based on administration of TXA, with differences assessed using Pearson's chi-square test for categorical variables and Student's Results: Of 406 patients (812 breasts), 213 patients (426 breasts) were administered TXA perioperatively. Neither group had significant differences in Caprini score, prior history of DVT, or anemia. Multivariable regression analysis, controlling for differences in demographics and operative characteristics, demonstrated that TXA use was significantly associated with decreased rates of dehiscence (aOR = 0.50, 95% CI 0.28-0.91, Conclusion: Intravenous TXA use in reduction mammoplasty confers lower rates of postoperative wound complications, though its impact may be secondary to wound closure technique.

Indexed as

Outcomes studiesReduction mammoplastyRetrospective studiesTranexamic acidWound dehiscence

Identifiers

PMID41675564
PMCPMC12887721

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.